MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 182 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

    The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

  • Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

    VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

  • Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

    A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MnzlR5l1d3SxeHnjJGF{e2G7 M3fNVFMh|ryP MXi3NkBp M{CwZWROW09? MVrJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? Ml7aNlA2PzFyNkm=
A431 NW[y[GE6U2mwYYPlJGF{e2G7 Mn;FOUDPxE1? M1PUeFUhcA>? M1\rdWROW09? M3PSV3N2eHC{ZYPz[ZMhfGinIIPp[45idGmwZzDv[kBCc3RiYX7kJGVzcw>? M2mwR|IxPTdzME[5
HepG2 MUXDfZRwfG:6aXOgRZN{[Xl? MV[xNEDPxE1? MXiyOEBp NXnBWoR6TE2VTx?= MWnT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= M4nLe|IyOjB3OUK1
Sk-Hep1 NWTUfIJNS3m2b4TvfIlkKEG|c3H5 M17FS|ExKM7:TR?= NV7vcHFuOjRiaB?= MlPCSG1UVw>? NWewcG5KW2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj MnGxNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) M1\zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r5cVMh|ryP NUC1SmhvPSCm MUXEUXNQ NWXMcG1uUUN3ME2wMlE1KM7:TR?= NXnieHVxOjF{OEmyOlc>
K1 cells harbored PIK3CA (E542K+/+) NV3qXlRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF25WZY{KM7:TR?= NHHpPVM2KGR? MYPEUXNQ M2O0eGlEPTB;MD61NkDPxE1? NHj1R5IzOTJ6OUK2Oy=>
FTC133 cells harbored PTEN (allele deletion and R130+) NGTP[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLtN{DPxE1? MVq1JIQ> NF7qV49FVVOR NVjyR|VDUUN3ME2wMlE5KM7:TR?= MYmyNVI5QTJ4Nx?=
C643 cells harbored HRAS (G13R+/−) M2fTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S3TlMh|ryP M3TzNlUh\A>? M2nMeGROW09? MXvJR|UxRTBwMkeg{txO NFPVW4UzOTJ6OUK2Oy=>
Hth7 cells harbored NRAS (Q61R+/−) NXf2bGk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TFZVMh|ryP MVu1JIQ> MYfEUXNQ MoKyTWM2OD12LkWg{txO NEGyNG8zOTJ6OUK2Oy=>
TPC1 cells harbored RET/PTC1 rearrangement NFHt[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17CclMh|ryP MmfnOUBl MmHsSG1UVw>? MYLJR|UxRTBwNUmg{txO M1T5R|IyOjh7Mk[3
Hth74 M1;DTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLUN{DPxE1? MlrzOUBl NHLlS|FFVVOR M3zTRmlEPTB;Mj6xPUDPxE1? M2rtdlIyOjh7Mk[3
KAT18 M1LwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\tU|VlOyEQvF2= NYC3V25oPSCm NVX3NFNWTE2VTx?= MWfJR|UxRTRwNkKg{txO NIHENJUzOTJ6OUK2Oy=>
SW1736 NWCxOHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWSzcY1WOTByIN88US=> NHvocWo2KGR? NFL5PWVFVVOR NELqVZdKSzVyPUS3MlU3KM7:TR?= NEnxc5IzOTJ6OUK2Oy=>
WRO Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGxNFAxKM7:TR?= MVm1JIQ> MorISG1UVw>? M1zK[mlEPTB-MUCwNEDPxE1? MXWyNVI5QTJ4Nx?=
TAD2 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNFAxKM7:TR?= NEK4NXg2KGR? M1vCcGROW09? MVPJR|UxRjFyMECg{txO MmPGNlEzQDl{Nke=
LN229 MUjBdI9xfG:|aYOgRZN{[Xl? NVvtdnRXOC53IN88US=> MXe2NEBp NVvMVYEzTE2VTx?= NX;lbGRwSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= Mmj5NlIxPTd7MUS=
T98G NEDIUXZCeG:ydH;zbZMhSXO|YYm= NInkXXkxNjVizszN MYq2NEBp NWTaO|I6TE2VTx?= MVTBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? Mn3vNlIxPTd7MUS=
HC11 NWnXVpFlTnWwY4Tpc44hSXO|YYm= NH31b5QyOCEQvF2= NH:3XY4zPCCq M1zTbGROW09? Ml\QTY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=> MmHYNlI1OjZ4MkG=
MOLT-4 MlzOR5l1d3SxeHnjJGF{e2G7 NWe2UnlKOTBizszN NUjWT3NTPDhiaB?= NH;pc49FVVOR MoPmTWM2OD1zLkhihKnPxE1? MWmyNlYyPDJ2Mx?=
CEM-R MmDxR5l1d3SxeHnjJGF{e2G7 NGfPeGwyOCEQvF2= MmnOOFghcA>? NHSybXJFVVOR M4PuXmlEPTB;Mz6z5qCK|ryP NGfpb|IzOjZzNEK0Ny=>
CEM-S MUXDfZRwfG:6aXOgRZN{[Xl? NWTpOpc5OTBizszN Mk\MOFghcA>? MmDaSG1UVw>? NVq3eYZ[UUN3ME21MlHjiIoQvF2= MkC1NlI3OTR{NEO=
MOLT-4 NXvTSGN4TnWwY4Tpc44hSXO|YYm= M{Wzb|ExKM7:TR?= MV6yOEBp MYLEUXNQ MYTCcI9kc3NiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNmKG:oIITo[UBk\WyuIHP5Z4xm NGDPOIIzOjZzNEK0Ny=>
MOLT-4 NEXtVWNHfW6ldHnvckBCe3OjeR?= M2nQdVTjiIoQvF2= MUe0JIg> MUTEUXNQ M3HtUmlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFOzRU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MV6yNlYyPDJ2Mx?=
CEM-R NF7GdmZHfW6ldHnvckBCe3OjeR?= M1v6bFTjiIoQvF2= NF\mV3g1KGh? MULEUXNQ MoriTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz NVPNPGNxOjJ4MUSyOFM>
CEM-S NGr6TVBHfW6ldHnvckBCe3OjeR?= MoLUOQKBkc7:TR?= NXrxSIVDPCCq NFSwdmNFVVOR MX\JcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> M2\aZ|IzPjF2MkSz
HepG2 cell MmO5T4lv[XOnIFHzd4F6 M1;s[|IxKM7:TR?= NFjLdGYzPCCq M4C3b2ROW09? MnfFSI94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MYeyN|c6PzNzOR?=
HepG2 cell M4H5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\KNm4{OCEQvF2= MUGyOEBp NV\iNJpYTE2VTx?= MWjJcohq[mm2czDj[YxtKGe{b4f0bC=> Mn7kNlM4QTd|MUm=
HepG2 cell MVrBdI9xfG:|aYOgRZN{[Xl? MoLKNlAh|ryP NVTybGlYOjRiaB?= NVLoS2YxTE2VTx?= NI[3[mRKdmS3Y3XzJINmdGxiYYDvdJRwe2m| Mnm1NlM4QTd|MUm=
GEO NFvp[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XHdFUxOCCwTR?= Mn;6O|IhcA>? M3exdmROW09? MVXJcohq[mm2czDj[YxtKGe{b4f0bC=> M3XxPFI1PThzMkOx
CNE-1 NUPqcXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ftZ|ExKM7:TR?= NXe0PVA5QTZiaB?= MoixSG1UVw>? M2LWTmlEPTB;Mj65OkDPxE1? NEfJbFgzPTN|NkmyOS=>
CNE-2 M1\sPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTZNVAh|ryP MX[5OkBp NHTZWXdFVVOR NFX5Z|hKSzVyPUSuOVMh|ryP M1ixXFI2OzN4OUK1
HONE-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkOlExKM7:TR?= MWq5OkBp M4fnTWROW09? NYnJeoFMUUN3ME2zMlM4KM7:TR?= NFfkd|gzPTN|NkmyOS=>
SUNE-1 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTWNVAh|ryP MYK5OkBp NXPiNpRjTE2VTx?= MV7JR|UxRTBwNUKg{txO NYfPbGplOjV|M{[5NlU>
CNE-2 NFXpbXNHfW6ldHnvckBCe3OjeR?= M4G2cVExKM7:TR?= Mn;nOFghcA>? NWDyRot{TE2VTx?= M{\uTGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? NGHpV2ozPTN|NkmyOS=>
HONE-1 MWPGeY5kfGmxbjDBd5NigQ>? NGC2[2YyOCEQvF2= M2XOWFQ5KGh? NYqwcI9yTE2VTx?= M2LKR2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? MV6yOVM{Pjl{NR?=
NEC8 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEm2OVEh|ryP MknxV2FPT0WU
P12-ICHIKAWA MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPZUWpRUUN3ME2wMlEyPjJizszN NYPURpBbW0GQR1XS
MDA-MB-175-VII M1i2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O4[WlEPTB;MD6xN|c{QCEQvF2= MlzLV2FPT0WU
AsPC-1 M{TIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfZRXNKSzVyPUCuNlIyOjJizszN NGrINHhUSU6JRWK=
T47D MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn3fnAxUUN3ME2wMlI5OjVizszN NYLabZU5W0GQR1XS
HH MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvGXYxKSzVyPUCuN|AzQDNizszN M2LSSnNCVkeHUh?=
MOLT-16 NUHTUJBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwM{CzNkDPxE1? NGrB[JRUSU6JRWK=
ES5 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwM{S0OVUh|ryP M2nq[HNCVkeHUh?=
RS4-11 NH;1cGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3OmlEPTB;MD6zOFYyKM7:TR?= M4OwN3NCVkeHUh?=
KARPAS-45 NHG2V|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Tj[mlEPTB;MD6zO|MzOSEQvF2= M16zVnNCVkeHUh?=
NCI-H720 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwM{e2O|kh|ryP MkDDV2FPT0WU
H9 M2DOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WxNGlEPTB;MD6zPFg5OyEQvF2= MmfFV2FPT0WU
EFM-19 NFrSdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP4cXliUUN3ME2wMlQ1ODFizszN NIDCWlBUSU6JRWK=
SBC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjoToxnUUN3ME2wMlQ1ODN3IN88US=> NIjOem9USU6JRWK=
A4-Fuk NWHWUWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjkO5dKSzVyPUCuOFY5PjhizszN NYi4dlJwW0GQR1XS
NCI-H1563 NHzsSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzFcHJKSzVyPUCuOFgyQDlizszN M{XsOHNCVkeHUh?=
HCC1419 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvHTWM2OD1yLkS4PFkzKM7:TR?= MXfTRW5ITVJ?
H-EMC-SS M13hO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7KUXJXUUN3ME2wMlQ6QTN7IN88US=> MX7TRW5ITVJ?
BHT-101 NUX4[XF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\YTWM2OD1yLkWyPVYyKM7:TR?= NEHVenFUSU6JRWK=
IGROV-1 M2HDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwNUWyOFkh|ryP MXTTRW5ITVJ?
HGC-27 NHH1ZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\wd4wzUUN3ME2wMlU3Pzh|IN88US=> NWD1UmhQW0GQR1XS
MDA-MB-361 M3nVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOxfXhKSzVyPUCuOVc4PjFizszN NGrJflBUSU6JRWK=
KE-37 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTrTWM2OD1yLkW4NlYh|ryP M3jYXHNCVkeHUh?=
HCC70 NU\D[5RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXtO4ZKSzVyPUCuOVk5OjdizszN M1vSNHNCVkeHUh?=
LNCaP-Clone-FGC NYDnVYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULtUZBlUUN3ME2wMlYyODR6IN88US=> MVLTRW5ITVJ?
HAL-01 M3rzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOzVIduUUN3ME2wMlYzOTNizszN NFzldWFUSU6JRWK=
HT M32xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jFS2lEPTB;MD62N|I{QSEQvF2= NVPOUoR{W0GQR1XS
MDA-MB-415 NYq2UINQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrIUJAyUUN3ME2wMlY{PjJ4IN88US=> M2K1d3NCVkeHUh?=
NOS-1 M{\O[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwNkO3NlMh|ryP M17ER3NCVkeHUh?=
DU-145 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrtTWM2OD1yLk[0O|Q2KM7:TR?= M{W1O3NCVkeHUh?=
OCUB-M NFLKWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e2RWlEPTB;MD63NFk3PiEQvF2= M2jmRnNCVkeHUh?=
VA-ES-BJ Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwN{OwNlUh|ryP MYHTRW5ITVJ?
J-RT3-T3-5 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwN{S0NFMh|ryP MlGyV2FPT0WU
MOLT-4 M4jwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwOEC1PFIh|ryP MmPoV2FPT0WU
NB7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zhXmlEPTB;MD64NlQyOSEQvF2= MmnWV2FPT0WU
L-363 M3y5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwOEO0OFIh|ryP NHHVfnBUSU6JRWK=
NKM-1 NEj4UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3HVGFKSzVyPUCuPFYzPTNizszN MXnTRW5ITVJ?
HOP-92 MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPCTWM2OD1yLki3NlI{KM7:TR?= NHfOWWJUSU6JRWK=
OAW-42 NX3mcXZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LC[WlEPTB;MD64PFczKM7:TR?= M{nwR3NCVkeHUh?=
HuO9 NIr6b4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HCeWlEPTB;MD65Nlc2OSEQvF2= NUjMXlRxW0GQR1XS
MFE-280 NVrBTZNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rPNWlEPTB;MD65OlQ3PSEQvF2= M4TtXXNCVkeHUh?=
EM-2 NV\re2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwOUe5N|kh|ryP MlT4V2FPT0WU
NCI-H520 M1KwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKSoZDUUN3ME2wMlk5PTl{IN88US=> M1fyd3NCVkeHUh?=
LB2241-RCC NXLyR|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwOUm3N|Qh|ryP MXnTRW5ITVJ?
SK-NEP-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTUTWM2OD1zLkG0OFg2KM7:TR?= NXfHOnpmW0GQR1XS
LXF-289 NHfje|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFwMUexOVYh|ryP MmKzV2FPT0WU
EPLC-272H MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW4XplKSzVyPUGuNVczPTZizszN NEfYfJNUSU6JRWK=
COLO-684 M{X2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T1e2lEPTB;MT6yN|czPSEQvF2= MV\TRW5ITVJ?
ES1 M1zNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPvU|Q6UUN3ME2xMlI1ODZ3IN88US=> MVjTRW5ITVJ?
DOHH-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXmc4VKSzVyPUGuNlgzODNizszN MnPuV2FPT0WU
CTB-1 NYWyOZViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPSfG5LUUN3ME2xMlI5QTlizszN M1LyVnNCVkeHUh?=
G-401 NHnsVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTxRohKSzVyPUGuNlk4QTVizszN MYfTRW5ITVJ?
LoVo NV7jVJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrKOG5DUUN3ME2xMlMzPTN2IN88US=> M3jrdHNCVkeHUh?=
Ramos-2G6-4C10 NWThTVZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTXTVhKSzVyPUGuN|M4ODFizszN NUWwWo1PW0GQR1XS
MFM-223 NV3hfWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwM{S0OlEh|ryP MYPTRW5ITVJ?
PA-1 NFzwO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwM{WyOlUh|ryP MWXTRW5ITVJ?
697 NVK4fYdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDrfG9KSzVyPUGuN|c3OTZizszN NVnzfIlwW0GQR1XS
QIMR-WIL Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrXO4E1UUN3ME2xMlQ6OTF4IN88US=> M1vneXNCVkeHUh?=
HOS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkezTWM2OD1zLkS5OVU5KM7:TR?= MVLTRW5ITVJ?
DMS-273 NVfhb|BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET2NIRKSzVyPUGuOVE6PTlizszN MYLTRW5ITVJ?
ME-180 NIXSUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\RTWM2OD1zLkW2PFkyKM7:TR?= NYTISZBPW0GQR1XS
HCC2218 M1T4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwNkiyNlUh|ryP MUnTRW5ITVJ?
CAL-54 NXyzOoVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4niZWlEPTB;MT63NVI1OiEQvF2= NFS1dY1USU6JRWK=
OMC-1 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTqTWM2OD1zLke0Olc4KM7:TR?= M2fQbHNCVkeHUh?=
COR-L105 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj4PJVSUUN3ME2xMlc6PzN5IN88US=> NIfLV|JUSU6JRWK=
BV-173 NWr1UVJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe0VmxKSzVyPUGuPFExPzRizszN MlP5V2FPT0WU
RKO NGHCe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TXfWlEPTB;MT64O|ExOSEQvF2= MkjDV2FPT0WU
SNU-387 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3STWM2OD1zLki4OFA3KM7:TR?= NX;yUWVwW0GQR1XS
SW1088 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwOUS2NFYh|ryP NWPHTYp3W0GQR1XS
Hs-578-T NIjUdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMUG0N|Mh|ryP Mn3EV2FPT0WU
OC-314 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILv[VlKSzVyPUKuNVUxQDZizszN NVK0TYRRW0GQR1XS
RMG-I NFvXbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwMU[zPVgh|ryP M4TBTnNCVkeHUh?=
NCI-H1395 NIjuZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn0TGdKSzVyPUKuNVgxQTFizszN NEHTV4dUSU6JRWK=
GAMG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJwMkO4OFUh|ryP M3frU3NCVkeHUh?=
LB1047-RCC NF61NpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\pRWlEPTB;Mj6yOFMyPyEQvF2= M{Lre3NCVkeHUh?=
MN-60 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJwMkm5NlMh|ryP MljOV2FPT0WU
OAW-28 NVjONlhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwMkm5OVEh|ryP NGX5OpNUSU6JRWK=
NCI-H2228 M3ixTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwM{G1OVIh|ryP NGrzR3NUSU6JRWK=
ABC-1 NH3ocVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonDTWM2OD1{LkOzNlU{KM7:TR?= MYrTRW5ITVJ?
LS-513 Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn1V4hKSzVyPUKuN|M1QDRizszN MmixV2FPT0WU
KS-1 NWXUfphbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrQN|BKSzVyPUKuN|gyQTFizszN NHLqXJJUSU6JRWK=
NB69 NXrE[3V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwM{i5PFMh|ryP NYL6UFRvW0GQR1XS
VM-CUB-1 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJwM{mwPFMh|ryP Mk\CV2FPT0WU
D-423MG NIL0W4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJwNEGwOFQh|ryP MlHHV2FPT0WU
EW-18 M1j1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwNEG5N|kh|ryP NX70NHlxW0GQR1XS
YH-13 M{LJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT5cYNmUUN3ME2yMlQ3OTV|IN88US=> Mo\kV2FPT0WU
T-24 NEL0XmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3CTWM2OD1{LkS3PFgyKM7:TR?= M{G4[3NCVkeHUh?=
ES8 M13mT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n6e2lEPTB;Mj60PVI5PyEQvF2= NYHDXo9LW0GQR1XS
ES3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrlU45zUUN3ME2yMlQ6PzV7IN88US=> NFrCT3lUSU6JRWK=
RXF393 NFj4bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwNkC0PFch|ryP NIPMdJlUSU6JRWK=
RPMI-8226 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\kNVVKSzVyPUKuOlI6PTNizszN NYizc45qW0GQR1XS
AGS M1n2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnuTWM2OD1{LkeyNVM4KM7:TR?= MUfTRW5ITVJ?
HCC1395 NWDQV3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJwN{WxPFch|ryP NGXEdoxUSU6JRWK=
MV-4-11 M2jofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrTmN[UUN3ME2yMlc2OjZ4IN88US=> MVzTRW5ITVJ?
A204 NH;mT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJwOEO4O|Ih|ryP M3H5[3NCVkeHUh?=
MCF7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJwOE[xNVch|ryP NGnhfpNUSU6JRWK=
SNU-423 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTwTWM2OD1{Lki5NlQzKM7:TR?= NVPsVHhIW0GQR1XS
NCI-H1048 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nkVmlEPTB;Mj65Olg3PSEQvF2= M3\UVnNCVkeHUh?=
GR-ST M2LrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;uTWM2OD1|LkC0OlEyKM7:TR?= NE\uWmxUSU6JRWK=
EoL-1- NF3seG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHnS2plUUN3ME2zMlA4ODV6IN88US=> MnG3V2FPT0WU
HuH-7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XOOGlEPTB;Mz6wPVQ3PCEQvF2= NXLJOGpQW0GQR1XS
OS-RC-2 NYPa[2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwMUGxPUDPxE1? NUjzeGFiW0GQR1XS
EW-3 NH6xNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLSTVNkUUN3ME2zMlE6PTJ7IN88US=> NXK2eWRbW0GQR1XS
NCI-H747 NYHwT|N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULMbWZHUUN3ME2zMlIxPjl2IN88US=> NHzGbXJUSU6JRWK=
EW-16 NGnVfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzUPZpNUUN3ME2zMlIyQDd7IN88US=> NHiyRmVUSU6JRWK=
DOK M1TVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzzcIhKSzVyPUOuNlI5PTlizszN M{PKeHNCVkeHUh?=
HCC2157 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD1|LkO4NVc6KM7:TR?= NFnCS|lUSU6JRWK=
OVCAR-3 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwNEC3PFYh|ryP NHrXUZZUSU6JRWK=
NCI-H1623 M3HUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3qTWM2OD1|LkSxNlI1KM7:TR?= MVnTRW5ITVJ?
H4 NESzcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwNEW2NlYh|ryP NIS3fHZUSU6JRWK=
SW1710 NGDoUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPkWVRSUUN3ME2zMlQ3Pjd6IN88US=> NGLHN4hUSU6JRWK=
RT-112 NXH1UZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm2NIZ[UUN3ME2zMlUzOzh6IN88US=> MXzTRW5ITVJ?
DMS-114 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPYW2Z6UUN3ME2zMlYzOjd6IN88US=> NESxTIpUSU6JRWK=
AN3-CA NE\RPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnKTWM2OD1|Lk[yOFU3KM7:TR?= MnGzV2FPT0WU
KNS-62 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr0fmNKSzVyPUOuOlM{OzhizszN Mn;wV2FPT0WU
SJRH30 NFSxVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYixfmhNUUN3ME2zMlY6OTJ{IN88US=> M4LBXXNCVkeHUh?=
G-402 NX36NJdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Ph[2lEPTB;Mz63NFcyOSEQvF2= NWGzeG9wW0GQR1XS
MHH-PREB-1 M1faV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ZTWM2OD1|LkeyNFM5KM7:TR?= NV30V|JJW0GQR1XS
P30-OHK MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LJSmlEPTB;Mz64NFk4PiEQvF2= MWXTRW5ITVJ?
RVH-421 NEf4NJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwOEG3PFgh|ryP MnTlV2FPT0WU
LU-134-A NFHJNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTNwOEi0Nlgh|ryP NF;vO5hUSU6JRWK=
ECC10 NXSzZmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\pOoZLUUN3ME2zMlk{PjJ{IN88US=> M4i3UnNCVkeHUh?=
TGW MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq1bJFKSzVyPUSuNFI{ODVizszN M3\jfnNCVkeHUh?=
MLMA M2nmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRwMEK5OlYh|ryP NWntV|F5W0GQR1XS
SCC-25 NV3rcVBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRwME[1OlYh|ryP MkX5V2FPT0WU
TYK-nu MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm3b25KSzVyPUSuNFk2OzRizszN M3HWTnNCVkeHUh?=
LAMA-84 NXu3VpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f5NGlEPTB;ND6xOFE6OSEQvF2= Mn;hV2FPT0WU
Calu-3 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\WfmlEPTB;ND6yOFQyPiEQvF2= NVTxN4hPW0GQR1XS
NCI-H460 NH3BSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK4TWM2OD12LkK2OFQ{KM7:TR?= MXjTRW5ITVJ?
EGI-1 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3GTWM2OD12LkO3O|c5KM7:TR?= NWfpdlF2W0GQR1XS
NCI-H292 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRwM{ixOFYh|ryP NITYS3hUSU6JRWK=
HCE-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPnRol3UUN3ME20MlQyPTd7IN88US=> M4f0W3NCVkeHUh?=
EW-11 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXoTWM2OD12LkSxPFM5KM7:TR?= M3\ocXNCVkeHUh?=
ATN-1 NGHCeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OxPWlEPTB;ND60OFMxPCEQvF2= MYnTRW5ITVJ?
NB5 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRwNUO2PVch|ryP NIW3c21USU6JRWK=
KLE M33vPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHvcGpKSzVyPUSuO|AyQThizszN NYr0NINJW0GQR1XS
CAL-39 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjyTWM2OD12LkeyNVQ3KM7:TR?= MVPTRW5ITVJ?
TI-73 NEjZeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XtVGlEPTB;ND64NFYxQSEQvF2= M2fPNXNCVkeHUh?=
HO-1-N-1 M3Pl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3uemJuUUN3ME20Mlk1OiEQvF2= NF;YTVNUSU6JRWK=
786-0 M1XTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTRwOUS2O|Mh|ryP NH7GSVRUSU6JRWK=
SK-N-DZ NIjzSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYroPI44UUN3ME20Mlk3OTR{IN88US=> NEDO[YpUSU6JRWK=
NCI-H446 NYT4XJh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTVwMkCwNFkh|ryP MoTmV2FPT0WU
ETK-1 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL5RpBKSzVyPUWuNlEyPjVizszN NYfNdY5CW0GQR1XS
BT-20 M3fkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHIdIxKSzVyPUWuNlE{PTNizszN MX\TRW5ITVJ?
MEL-HO M2LBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nEN2lEPTB;NT6zO|M{PiEQvF2= MmrRV2FPT0WU
CAL-27 M1XWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjRZ3lvUUN3ME21MlQ3OzN7IN88US=> MnXrV2FPT0WU
SW872 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr4eo1KSzVyPUWuOVk1OjhizszN MnjqV2FPT0WU
RPMI-2650 M1f3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnBSJhyUUN3ME21MlY3OTl7IN88US=> M3Hi[XNCVkeHUh?=
PFSK-1 NWnOV2pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTVwN{K3N|Ih|ryP MUDTRW5ITVJ?
SF295 NInQWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPyR|ZKSzVyPUWuPFA3OzNizszN NV34bm5uW0GQR1XS
Becker MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnpNmNzUUN3ME21Mlg3PDd{IN88US=> MlvnV2FPT0WU
Saos-2 NHL3dXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjmNo1KSzVyPUWuPFY2OyEQvF2= MVTTRW5ITVJ?
SK-OV-3 NHmwNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nT[2lEPTB;NT65PVgyPiEQvF2= NYj5TJc3W0GQR1XS
VMRC-RCZ NXrPPVd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTZwMEi3O|Mh|ryP NWX4OoJYW0GQR1XS
EW-22 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq3[WFvUUN3ME22MlE6PjR7IN88US=> Mmf4V2FPT0WU
BT-474 NE\wdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTZwMkOzJO69VQ>? M1Pn[HNCVkeHUh?=
BFTC-909 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf3W2g1UUN3ME22MlMxOzR3IN88US=> MXjTRW5ITVJ?
NB12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\pe3VoUUN3ME22MlM6ODdzIN88US=> NImzN4ZUSU6JRWK=
D-263MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXITWM2OD14LkS1NVY6KM7:TR?= M2DzS3NCVkeHUh?=
SNB75 M17l[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PVVmlEPTB;Nj62NFE1OyEQvF2= M{DpVXNCVkeHUh?=
A704 M{jKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZwNkOwOkDPxE1? NVu1[JREW0GQR1XS
NCI-H1693 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZwNkO2NFQh|ryP NXvMSHFJW0GQR1XS
LN-405 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\4bW9KSzVyPU[uO|k3PzJizszN M4CySXNCVkeHUh?=
CHL-1 NXHsfWVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnWS5FkUUN3ME22MlgxODd7IN88US=> NUX0W5lQW0GQR1XS
A498 NWDDTnlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjQ[pl6UUN3ME22MlgyQTZzIN88US=> M1LIbnNCVkeHUh?=
TE-12 NYTNWZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nNdGlEPTB;Nj64N|gyPyEQvF2= MVXTRW5ITVJ?
TE-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZwOUOwN|gh|ryP MYTTRW5ITVJ?
AU565 M1G4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnCSIxKSzVyPU[uPVY6PTdizszN NEHET4pUSU6JRWK=
RD NVPJflJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XkO2lEPTB;Nj65PFI5PCEQvF2= NFTIfoRUSU6JRWK=
SW1463 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPPXZVKSzVyPUeuNVEyPjhizszN NVrSZ21tW0GQR1XS
LU-99A NGK0XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfZdmFKSzVyPUeuNVQ{OjJizszN MWfTRW5ITVJ?
NCI-H28 M4HaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\FTWM2OD15LkK5NlQh|ryP NE[yVHhUSU6JRWK=
MC-IXC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrT[IhyUUN3ME23MlQ5PTd4IN88US=> MXTTRW5ITVJ?
GP5d MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrJcnNmUUN3ME23MlQ5PzZ2IN88US=> M3nBe3NCVkeHUh?=
GB-1 NEXyWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nWNmlEPTB;Nz61OFgxPCEQvF2= M{PJc3NCVkeHUh?=
CAL-33 NWLMUVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK1XJBIUUN3ME23MlY3OjN|IN88US=> NGXZTnlUSU6JRWK=
MSTO-211H MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXwcHF1UUN3ME23MlY4OzN4IN88US=> NU\QOos2W0GQR1XS
TE-5 NGrIdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fqUGlEPTB;Nz63PVM{PCEQvF2= MYXTRW5ITVJ?
D-566MG MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3La[WlEPTB;OD6wOFQzQSEQvF2= Ml;pV2FPT0WU
JVM-3 M4fURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qwVWlEPTB;OD6xOVI3QCEQvF2= NGjvS3lUSU6JRWK=
T98G MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRThwMUiwOlch|ryP MXzTRW5ITVJ?
HCC1954 NUW4TWhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DSc2lEPTB;OD60OVExPCEQvF2= M1\PXHNCVkeHUh?=
SF126 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRThwNEW5N|Yh|ryP NUTkcodYW0GQR1XS
LB996-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnORXhyUUN3ME24MlU{OjV5IN88US=> Mn3oV2FPT0WU
SKG-IIIa NVrvTnpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRThwNkOwOlkh|ryP NHjUeVdUSU6JRWK=
NCI-SNU-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDk[VJOUUN3ME24MlY1PjR|IN88US=> M4DUS3NCVkeHUh?=
LB771-HNC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XSRWlEPTB;OD62OFY6PiEQvF2= NY\WdWJYW0GQR1XS
SCC-4 NV3BbW1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf2[5ZLUUN3ME24MlY5OjF7IN88US=> NX3CXohXW0GQR1XS
CAMA-1 NYXwflE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36wZWlEPTB;OD63O|E1PiEQvF2= NH7SZ45USU6JRWK=
D-502MG NE[wVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLTWndKSzVyPUiuO|g3OjlizszN NYiweXE3W0GQR1XS
ESS-1 NFrw[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRThwOEi3NFQh|ryP NFTDW3RUSU6JRWK=
HEC-1 NHj0PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLkTZFnUUN3ME24Mlg6QDZ4IN88US=> M2rXTHNCVkeHUh?=
NB10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL6XGJpUUN3ME25MlAzOjJ2IN88US=> MYfTRW5ITVJ?
8505C M3frcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\5TWM2OD17LkC0NlMzKM7:TR?= NULqc4xyW0GQR1XS
EFO-27 NEnySGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDkTWM2OD17LkG2OFEzKM7:TR?= MmPHV2FPT0WU
HN M1jqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC2PFlKSzVyPUmuNVY3OjhizszN NV7kS3d7W0GQR1XS
DSH1 NV7BPHBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkftTWM2OD17LkKwPFch|ryP M4L2OnNCVkeHUh?=
NBsusSR MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTlwMke0NFIh|ryP NInSW25USU6JRWK=
LS-123 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTlwM{G3OlEh|ryP MWLTRW5ITVJ?
SHP-77 NXTiNlNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTlwM{m5N|Uh|ryP MorkV2FPT0WU
ACN NVrINFlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvuTWM2OD17LkWzNlc4KM7:TR?= MojUV2FPT0WU
U251 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MneyTWM2OD17Lk[1OVQ1KM7:TR?= Mmm0V2FPT0WU
A431 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXSwRXZ[UUN3ME25MlgxOjN6IN88US=> NH71VXVUSU6JRWK=
5637 M{nudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3XN482UUN3ME25Mlg1QTh2IN88US=> MVjTRW5ITVJ?
MDA-MB-157 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r4TWlEPTB;OT65Nlg4QCEQvF2= MlnlV2FPT0WU
A101D M4nZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTYOmNQUUN3ME25Mlk6QTd2IN88US=> NGTqW2dUSU6JRWK=
YKG-1 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFyLkKwNFYh|ryP NIf0UnVUSU6JRWK=
LAN-6 NUfqToFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXnTWM2OD1zMD6yNVY1KM7:TR?= NVL6WVdFW0GQR1XS
OVCAR-5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFyLkK0N|Mh|ryP M{DwOnNCVkeHUh?=
A549 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvDTWM2OD1zMD6zPVc{KM7:TR?= MV;TRW5ITVJ?
no-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C4TWlEPTB;MUCuOFM2OyEQvF2= M33TcHNCVkeHUh?=
SF539 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFyLkmwOFEh|ryP NW\TO2JjW0GQR1XS
A388 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnHXolKSzVyPUGxMlM5QTdizszN NILpWpNUSU6JRWK=
DEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFzLkSyOEDPxE1? MkDsV2FPT0WU
SW954 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFzLkS2Olgh|ryP NIHwOG9USU6JRWK=
TK10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFzLkWyO|Eh|ryP MVfTRW5ITVJ?
SW756 NH7DO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILXUINKSzVyPUGxMlUzQTRizszN NYXKc|NOW0GQR1XS
PC-3 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzLkW3OlQh|ryP NGXESIFUSU6JRWK=
ONS-76 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFzLk[zOkDPxE1? M4C0OnNCVkeHUh?=
A427 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vweWlEPTB;MUGuO|A6OyEQvF2= MXfTRW5ITVJ?
MEG-01 NUfSeWpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PDXGlEPTB;MUGuO|UxQSEQvF2= NW\1VGxJW0GQR1XS
BB30-HNC M3\Yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zLW2lEPTB;MUGuO|k5OiEQvF2= NVr3enlGW0GQR1XS
NCI-H1299 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfPfY9bUUN3ME2xNU45ODl|IN88US=> NV;1clBLW0GQR1XS
GCT NEDH[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17heWlEPTB;MUGuPFIzQCEQvF2= NIW1eYpUSU6JRWK=
D-247MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvTTWM2OD1zMT65OlY{KM7:TR?= M{\6[HNCVkeHUh?=
CFPAC-1 NVi4PG5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK2cIVKSzVyPUGxMlk4QDJizszN NV;oeplRW0GQR1XS
EKVX MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TNdWlEPTB;MUKuNFMyOyEQvF2= NYDGb3RxW0GQR1XS
CAL-51 M3jmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX76[5duUUN3ME2xNk4xPzF4IN88US=> MkLtV2FPT0WU
BB49-HNC NH\TU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfJSZlKSzVyPUGyMlEyPzdizszN NWTq[FhkW0GQR1XS
RPMI-7951 NYDKU4hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X1dmlEPTB;MUKuNVg2PCEQvF2= NUD5VnozW0GQR1XS
RH-1 NGrtfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF{LkKxPFQh|ryP NFWxd5hUSU6JRWK=
BCPAP Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrJVFhYUUN3ME2xNk41PzR7IN88US=> MVXTRW5ITVJ?
GCIY MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;u[mlEPTB;MUKuOVIxQSEQvF2= NGjJSGtUSU6JRWK=
KNS-81-FD MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XFRmlEPTB;MUKuOVg3QSEQvF2= M1vQc3NCVkeHUh?=
KYSE-140 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkiyTWM2OD1zMj64OVk2KM7:TR?= NFXI[2FUSU6JRWK=
Ca-Ski MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF{LkmwOFEh|ryP Ml7FV2FPT0WU
TGBC1TKB M{D0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF{LkmxNVUh|ryP M4HZNnNCVkeHUh?=
HCC1187 NFzNfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKyfnBUUUN3ME2xN{4yQTF{IN88US=> MnvzV2FPT0WU
SJSA-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TCbGlEPTB;MUOuNlMzPyEQvF2= NX;GSVlwW0GQR1XS
CTV-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET3XWJKSzVyPUGzMlM1PSEQvF2= MnXGV2FPT0WU
WM-115 NXrJXmttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF|Lk[0PFMh|ryP M2n6NnNCVkeHUh?=
CHP-212 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF|Lkm3N|kh|ryP NGnzcplUSU6JRWK=
SCC-15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS5XIdKSzVyPUGzMlk4PzVizszN M4TmV3NCVkeHUh?=
BPH-1 NHLTWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33uUWlEPTB;MUSuNVY3PCEQvF2= M3TTcXNCVkeHUh?=
SW780 NGrVeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjaTWM2OD1zND61NFI2KM7:TR?= NVvvRW1oW0GQR1XS
NCI-H2291 NF\5c2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\xe2lEPTB;MUSuOVg4QCEQvF2= NVHPdVI3W0GQR1XS
JEG-3 NV;qR2xwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF2Lk[zNlYh|ryP NIPVT2JUSU6JRWK=
CAL-120 NVO2cGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF2LkewNlch|ryP NUD2U49wW0GQR1XS
NCI-H23 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq1TWM2OD1zND63PVk4KM7:TR?= NHjJbIhUSU6JRWK=
MS-1 MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLTUJZIUUN3ME2xOE46PjFzIN88US=> MUPTRW5ITVJ?
PC-14 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PZSmlEPTB;MUSuPVY2PCEQvF2= MojnV2FPT0WU
D-283MED M4LhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELyT2VKSzVyPUG1MlAyOTFizszN M4HWOHNCVkeHUh?=
OE19 M{nxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3vdJpKUUN3ME2xOU4yPTRzIN88US=> Mk\kV2FPT0WU
CAS-1 M3\zZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH75RYxKSzVyPUG1MlQyQDRizszN MYrTRW5ITVJ?
NCI-H727 M1rZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ybGlEPTB;MUWuOFIzOSEQvF2= M{HVUnNCVkeHUh?=
SiHa M2n0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TWeWlEPTB;MUWuO|U6PCEQvF2= NX3sc3N[W0GQR1XS
BFTC-905 M3TnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrwWG9OUUN3ME2xOU44Pjl2IN88US=> NFnyNolUSU6JRWK=
MDA-MB-453 M3jUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzWTWM2OD1zNj6xOlQzKM7:TR?= M{L0bHNCVkeHUh?=
HuP-T3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD1zNj62N|c{KM7:TR?= NYD0Nmc{W0GQR1XS
SK-LU-1 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe3RZNKSzVyPUG2MlY6PTZizszN NEjPWYNUSU6JRWK=
Detroit562 NHnL[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojrTWM2OD1zNj63N|E5KM7:TR?= NGPwZoVUSU6JRWK=
HCC1569 NUDWSZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfnNHRKSzVyPUG2Mlg{OzdizszN NXvoOVlPW0GQR1XS
SK-MES-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\oRVU5UUN3ME2xOk45PDF7IN88US=> NGTLZ2VUSU6JRWK=
BB65-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKyPVZKSzVyPUG3MlA1PzlizszN Ml;RV2FPT0WU
LOXIMVI NEfXcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPaVopKUUN3ME2xO{4xPzB5IN88US=> NVHNOnBCW0GQR1XS
SW1783 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF5LkGyPEDPxE1? M{CyWXNCVkeHUh?=
NH-12 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Ln[2lEPTB;MUeuN|MxOyEQvF2= MljpV2FPT0WU
UACC-257 M3qz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnviTWM2OD1zNz61OVEzKM7:TR?= NUfyN3B1W0GQR1XS
KOSC-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqxTWM2OD1zNz62O|U4KM7:TR?= NF3wVo5USU6JRWK=
KG-1 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjhWG5bUUN3ME2xO{43QTN5IN88US=> MVnTRW5ITVJ?
M059J M1XESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT6TWM2OD1zNz63NFMh|ryP MoPnV2FPT0WU
MHH-NB-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu1XlFkUUN3ME2xO{46Pjd|IN88US=> NX;RU3BFW0GQR1XS
EW-1 M332[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF6LkGzPFIh|ryP MmrWV2FPT0WU
CAL-85-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPmTWM2OD1zOD6yN|U4KM7:TR?= Mkm3V2FPT0WU
639-V NUHVOI9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPBclBzUUN3ME2xPE4{OzV2IN88US=> M1LMWXNCVkeHUh?=
C32 NF36d|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF6LkS3Nlch|ryP NGfFWFhUSU6JRWK=
KM-H2 MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUeyWVNQUUN3ME2xPE42OjN{IN88US=> MlTiV2FPT0WU
A253 NH;XR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF6LkeyPFYh|ryP MnmwV2FPT0WU
NCI-N87 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\TS441UUN3ME2xPE46ODB6IN88US=> MYDTRW5ITVJ?
8-MG-BA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXFbm9KSzVyPUG5MlA3PDZizszN NUfzXXduW0GQR1XS
GI-ME-N MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rrSGlEPTB;MUmuNVU1PiEQvF2= NHLw[5dUSU6JRWK=
8305C MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD1zOT6yNlg3KM7:TR?= NGHWNG1USU6JRWK=
TE-8 M3XZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PDPGlEPTB;MUmuN|AzPCEQvF2= MXXTRW5ITVJ?
KYSE-270 NXrFR4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zzXmlEPTB;MkCuNFIyPyEQvF2= M1TkO3NCVkeHUh?=
HL-60 NUjjR|BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjJTWM2OD1{MD6wPVQyKM7:TR?= MoPBV2FPT0WU
Mo-T NVXaUIt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjmcHJpUUN3ME2yNE4yPjZ3IN88US=> MVvTRW5ITVJ?
NCI-H1355 M{XYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O2SmlEPTB;MkCuN|M4PCEQvF2= MkjqV2FPT0WU
HT-1080 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT6[m1iUUN3ME2yNE42PDl5IN88US=> NYDiS5VbW0GQR1XS
MIA-PaCa-2 M2TR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTPPYFFUUN3ME2yNE43QDh|IN88US=> M1joT3NCVkeHUh?=
NCI-H441 NVrXemFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvubW06UUN3ME2yNE44Ozd7IN88US=> NF[2d2JUSU6JRWK=
LCLC-97TM1 M1P0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEezRW1KSzVyPUKwMlgyOzRizszN M2G1cHNCVkeHUh?=
HT-3 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLjfnFKSzVyPUKxMlU3OzFizszN MYLTRW5ITVJ?
22RV1 M4rn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LLTWlEPTB;MkGuOVY5PSEQvF2= NHG1d2JUSU6JRWK=
LK-2 NYXEfGRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPoVpdDUUN3ME2yNU42QTV|IN88US=> MmT4V2FPT0WU
CW-2 M{L1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LD[2lEPTB;MkGuOlA3QSEQvF2= NIC1VlJUSU6JRWK=
KYSE-510 NGnSc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHVTWM2OD1{MT62NFk2KM7:TR?= NEDG[mVUSU6JRWK=
CGTH-W-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJzLkexOlYh|ryP MXXTRW5ITVJ?
NCI-H661 NILxb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPWUplKSzVyPUKyMlA{PCEQvF2= M1qwcXNCVkeHUh?=
KU-19-19 NHTjXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzy[WpDUUN3ME2yNk4yPjl5IN88US=> NWjDT5czW0GQR1XS
NCI-H2122 NV3ubYJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO5e4dJUUN3ME2yNk4zPDN{IN88US=> MkHtV2FPT0WU
NCI-H526 NHXaNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ{LkO4PVUh|ryP MVHTRW5ITVJ?
NCI-H1650 NUf6c3N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ{Lke2OEDPxE1? Mn7WV2FPT0WU
AM-38 NY\qXHRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe5NnV4UUN3ME2yNk45Pjh7IN88US=> M4\6PHNCVkeHUh?=
NCI-H2405 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwcZZqUUN3ME2yN{4zPTN|IN88US=> M17tNHNCVkeHUh?=
M14 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3nZYJKSzVyPUKzMlQxQDhizszN Mlz3V2FPT0WU
ES4 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ|LkSyN|Ih|ryP NWDZdWZOW0GQR1XS
DJM-1 NYXYRoFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrXTWM2OD1{Mz61NlM1KM7:TR?= NEHYPG9USU6JRWK=
S-117 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLuTWM2OD1{Mz63OlUyKM7:TR?= MWHTRW5ITVJ?
MZ2-MEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TCSWlEPTB;MkOuO|c2QSEQvF2= NYi5ZmpoW0GQR1XS
SK-MEL-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPSWIpTUUN3ME2yN{45OTN|IN88US=> NY\RbXRFW0GQR1XS
HCC1806 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ|Lki3NFkh|ryP NVHSfG9bW0GQR1XS
NMC-G1 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlziTWM2OD1{ND6yNlI3KM7:TR?= NGXpW4RUSU6JRWK=
DK-MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrQXnVKSzVyPUK0MlI6PCEQvF2= MV7TRW5ITVJ?
SK-N-FI NUXxPXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ2LkOzNFIh|ryP NELhOIpUSU6JRWK=
KINGS-1 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnOVnJ[UUN3ME2yOE41QDd2IN88US=> MmjhV2FPT0WU
HCC2998 NVXaXohHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ2LkS4PFUh|ryP MnfKV2FPT0WU
ALL-PO NYPRR25OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HTbGlEPTB;MkSuOlE6KM7:TR?= MX7TRW5ITVJ?
MPP-89 NXz5WGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH1UYFWUUN3ME2yOU4xPDV6IN88US=> M2T1SXNCVkeHUh?=
NCI-H2342 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ3LkG5OVMh|ryP M2XQc3NCVkeHUh?=
TE-1 M{i5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3YTWM2OD1{NT6zOVY{KM7:TR?= NYjiZZp4W0GQR1XS
RH-18 M1f6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fQbGlEPTB;MkWuOVkyQCEQvF2= NEjVbWtUSU6JRWK=
HT-1376 M1jmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfrZ3B4UUN3ME2yOU43PDZ3IN88US=> Mm\LV2FPT0WU
U-2-OS MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq0TWM2OD1{NT62PFg5KM7:TR?= MXrTRW5ITVJ?
BT-549 M1LRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzX[WwyUUN3ME2yOU46ODFzIN88US=> NWntSWI3W0GQR1XS
NCI-H1755 M{LkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HtVWlEPTB;MkWuPVk1PSEQvF2= MY\TRW5ITVJ?
EW-13 NVTYelZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XsdGlEPTB;Mk[uNFI4PCEQvF2= NV3wR41LW0GQR1XS
NB13 M2LJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:2XJhPUUN3ME2yOk4xQTR7IN88US=> MWTTRW5ITVJ?
NUGC-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD1{Nj6yNVA{KM7:TR?= NET2cIVUSU6JRWK=
GMS-10 NXPLXmNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HFN2lEPTB;Mk[uNlM2OyEQvF2= NWe3eY1[W0GQR1XS
CHP-134 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnPSlhSUUN3ME2yOk4{QDZ5IN88US=> MUfTRW5ITVJ?
SW962 NVeyPHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ4LkWwNlEh|ryP Ml:2V2FPT0WU
SNU-449 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXOTWM2OD1{Nz6wPFA{KM7:TR?= NIjvTodUSU6JRWK=
HuP-T4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzMfm1KSzVyPUK3MlA5PzlizszN MV;TRW5ITVJ?
SW948 NUjJ[oJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT3U|RKSzVyPUK3MlE{PDRizszN NH7t[25USU6JRWK=
NCI-H226 M1HC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTKTWM2OD1{Nz60OVc5KM7:TR?= NVzjVXZtW0GQR1XS
SK-PN-DW MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3Pe45TUUN3ME2yO{43ODF{IN88US=> NX7SO5JJW0GQR1XS
GI-1 NHrLSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSzXYhKSzVyPUK3MlczOSEQvF2= MWrTRW5ITVJ?
CAL-12T NFvNXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDYPXZKSzVyPUK4MlEyOTJizszN MU\TRW5ITVJ?
YAPC MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELnUYJKSzVyPUK4MlI2PjRizszN NFTjXlBUSU6JRWK=
SNU-C2B MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTuTWM2OD1{OD6yPVY1KM7:TR?= MV;TRW5ITVJ?
RCC10RGB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvKTWM2OD1{OD61OFE4KM7:TR?= NF:yb4RUSU6JRWK=
ES7 M4DF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXmXWRKSzVyPUK5MlE1PjVizszN NVvYSHkxW0GQR1XS
PANC-03-27 NYXENnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSyNIdmUUN3ME2yPU41PDRizszN NIrTS|lUSU6JRWK=
ES6 NYPwfVZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ7LkixOVch|ryP M335SXNCVkeHUh?=
HT-1197 NEfOZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XVXGlEPTB;M{CuNFU6QCEQvF2= MVjTRW5ITVJ?
ZR-75-30 M3n2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nrU2lEPTB;M{CuNlM5OyEQvF2= M3HaVnNCVkeHUh?=
DB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjy[|NKSzVyPUOwMlQ6PDJizszN MoOzV2FPT0WU
OCI-AML2 M1vufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PyRmlEPTB;M{GuNFY6KM7:TR?= M2f3WnNCVkeHUh?=
NCI-H2170 NY\qOIpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn0TWM2OD1|MT64OVE3KM7:TR?= M17ENXNCVkeHUh?=
IST-MES1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX33NlY3UUN3ME2zNk4zQDl5IN88US=> MX\TRW5ITVJ?
769-P M4PMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN{LkO2OFEh|ryP NF3lU4lUSU6JRWK=
COR-L23 NETSW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrWbI5KSzVyPUOyMlkxPzNizszN NFTWbohUSU6JRWK=
SW626 NFTSbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLtTWM2OD1|Mz6xO|c3KM7:TR?= M2TIN3NCVkeHUh?=
LU-139 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fTd2lEPTB;M{OuOlYxPSEQvF2= M1[1R3NCVkeHUh?=
HT-144 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN|Lki2N{DPxE1? MlzQV2FPT0WU
CaR-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fKeWlEPTB;M{OuPVgzOiEQvF2= MWjTRW5ITVJ?
OE33 NH2wZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjafVN4UUN3ME2zOE4zQDV3IN88US=> MXXTRW5ITVJ?
COLO-800 M3q3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXlSHVvUUN3ME2zOE4{PjR5IN88US=> NYHJeW9{W0GQR1XS
NB14 NYfSPYV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvrPZZQUUN3ME2zOE41Pjh2IN88US=> M3nEXXNCVkeHUh?=
KURAMOCHI Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rT[GlEPTB;M{[uNVE6QCEQvF2= NHvxU21USU6JRWK=
SW48 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN4LkK0O|Qh|ryP NXvkNJVJW0GQR1XS
Daoy MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHuTWM2OD1|Nj62OVM5KM7:TR?= NIGzdFNUSU6JRWK=
TGBC24TKB M3X6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv6[mVKSzVyPUO2MlY4KM7:TR?= NVfrWZVyW0GQR1XS
DU-4475 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r3XWlEPTB;M{[uPVA{OyEQvF2= Mmi5V2FPT0WU
SW1417 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rkfGlEPTB;M{iuNFU2OiEQvF2= NGjjbJhUSU6JRWK=
EFO-21 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\aXWZKSzVyPUO4Mlk{PDlizszN MVXTRW5ITVJ?
MG-63 M1zXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN7LkO0NlQh|ryP MVzTRW5ITVJ?
LC-2-ad MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfMN|dzUUN3ME2zPU42PTF{IN88US=> M1X3R3NCVkeHUh?=
NOMO-1 M3XPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXVTWM2OD1|OT64Nlc1KM7:TR?= M2jPXHNCVkeHUh?=
COLO-741 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XhdGlEPTB;NECuNVMxPCEQvF2= MorKV2FPT0WU
BxPC-3 NHLs[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDBNG1KSzVyPUSwMlU3QDZizszN NHuzeXNUSU6JRWK=
HSC-2 NHXLXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rKfWlEPTB;NECuPVEyOyEQvF2= MXPTRW5ITVJ?
UMC-11 NXPqR3FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP5TWM2OD12MT6yOlMh|ryP Mn\oV2FPT0WU
HCC1937 NXfhbG5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXwWYFKSzVyPUSyMlc5PDNizszN NV\1cWlKW0GQR1XS
Calu-6 NVfxU5FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPqdJNKSzVyPUSzMlI{QDJizszN NWnhZ2RVW0GQR1XS
NCI-H1573 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD12Mz6zOFc4KM7:TR?= M3\meHNCVkeHUh?=
SK-N-AS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULJRVhyUUN3ME20N{43ODF7IN88US=> NFrwWFNUSU6JRWK=
PSN1 NXjafIM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV20TG1CUUN3ME20OU4zPTR6IN88US=> NYH1cY52W0GQR1XS
TE-11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTR3LkS4OFIh|ryP M4nrPXNCVkeHUh?=
NCI-H1155 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLVZoJbUUN3ME20OU45QTZ5IN88US=> Ml\HV2FPT0WU
KM12 NUTTbGl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjJTWM2OD12NT65NFc3KM7:TR?= Mni5V2FPT0WU
RO82-W-1 M3jsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HpZWlEPTB;NE[uPVgzOiEQvF2= NVntTGZKW0GQR1XS
SW1573 M4fKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M325U2lEPTB;NEeuN|c{PiEQvF2= MYrTRW5ITVJ?
CAKI-1 NWnUUJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HENGlEPTB;NEiuNlg1PSEQvF2= NIXSdHhUSU6JRWK=
U-118-MG NHPX[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH1TWM2OD12OD6zO|AzKM7:TR?= M4nUN3NCVkeHUh?=
KYSE-520 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ftWmlEPTB;NEiuOFAyPiEQvF2= NVS1PJVPW0GQR1XS
HT55 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS3VGkzUUN3ME20PU4yPDd2IN88US=> MV7TRW5ITVJ?
ChaGo-K-1 NIP0XlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnjS3lpUUN3ME20PU41Pzl|IN88US=> NWDjR49NW0GQR1XS
IA-LM MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvDVFlKSzVyPUW0MlY{OjJizszN MkizV2FPT0WU
UACC-62 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\XSXNKSzVyPUW1MlExPDZizszN M1X1NXNCVkeHUh?=
MKN7 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTMTWM2OD13Nj6wNlg2KM7:TR?= Ml3tV2FPT0WU
HPAF-II MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfJTWM2OD13Nj60NFc{KM7:TR?= MXXTRW5ITVJ?
NTERA-S-cl-D1 M{i2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3FTWM2OD13Nz63O|gh|ryP NEj3NYtUSU6JRWK=
FTC-133 NWe3Woh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD13OD6wPVY6KM7:TR?= NGraVnFUSU6JRWK=
MHH-ES-1 M17xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVftVmRvUUN3ME21PE41QDF2IN88US=> MWrTRW5ITVJ?
JVM-2 NY\ub3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTV6Lkm1NFYh|ryP M1H3fHNCVkeHUh?=
TCCSUP NWTP[Ix2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDMVGpKSzVyPUW5MlUzPzlizszN Mk\wV2FPT0WU
COLO-824 NYjMdoppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfpNJRKSzVyPU[wMlA4OTlizszN MnrvV2FPT0WU
647-V MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInoU|lKSzVyPU[wMlE{PDdizszN MmrlV2FPT0WU
HD-MY-Z NF\aVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K5fWlEPTB;NkCuOVI6PCEQvF2= NUj3N|VPW0GQR1XS
LS-411N M1nldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13NXGlEPTB;NkGuN|kxOyEQvF2= NVixS4ZQW0GQR1XS
NCI-H596 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTZ{Lke0PVYh|ryP MV7TRW5ITVJ?
C-33-A NEm4d3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZ2LkC5OVch|ryP M4G1SHNCVkeHUh?=
BHY M3KwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPkdmhCUUN3ME22OE4yOjR3IN88US=> MXPTRW5ITVJ?
KGN NHf5[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T6WmlEPTB;NkSuOVUyPCEQvF2= MWPTRW5ITVJ?
NCI-H1092 NIDjfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnzTWM2OD14NT6wNFk2KM7:TR?= M{jYeXNCVkeHUh?=
MZ1-PC NYO3fXRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:x[GlEPTB;NkWuOVY1QSEQvF2= NXX1RVU6W0GQR1XS
LB831-BLC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n4U2lEPTB;NkWuPFQ5OSEQvF2= MVTTRW5ITVJ?
SW620 M1W4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfxfVc1UUN3ME22Ok4zODN7IN88US=> NETHeIlUSU6JRWK=
HuO-3N1 NYHScldDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0RZdKSzVyPU[4MlMzOzhizszN NVqwO3FOW0GQR1XS
SK-HEP-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXBV|NZUUN3ME22PU46PDh4IN88US=> NEj3V49USU6JRWK=
LCLC-103H NFyz[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDITWM2OD15MD62O|A2KM7:TR?= NVnuOGpmW0GQR1XS
KYSE-70 NUjtSWYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zTWM2OD15MD63PFM2KM7:TR?= NEHM[ZFUSU6JRWK=
Mewo M2n2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTdzLkWwOUDPxE1? M4PXOHNCVkeHUh?=
COLO-668 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLw[41KSzVyPUexMlg1PTFizszN MUTTRW5ITVJ?
NCI-H522 NYLr[49LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTd{LkO0NVMh|ryP M1vBb3NCVkeHUh?=
NCI-H1437 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTd2LkSwOFgh|ryP NHewNWFUSU6JRWK=
U-266 M1vKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknPTWM2OD15NT60OVE3KM7:TR?= NFHxc5pUSU6JRWK=
MC116 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHaOmVKSzVyPUe1MlU4ODhizszN NY\QcIdTW0GQR1XS
PANC-10-05 NE\0XGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTd5LkSyOFMh|ryP NGfIflhUSU6JRWK=
KYSE-180 NGHBbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;aTWM2OD15Nz61OFU1KM7:TR?= M2nSXnNCVkeHUh?=
JAR M17jbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof0TWM2OD15OT6wOVQ3KM7:TR?= NIXnOVBUSU6JRWK=
CAL-62 NYHyUIVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj1VnJKSzVyPUiwMlA6PSEQvF2= M1q0[nNCVkeHUh?=
A3-KAW NIHUeVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC3V4RxUUN3ME24NE4zOTV2IN88US=> NIHSOY5USU6JRWK=
PANC-08-13 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M375TWlEPTB;OEGuNVc3QCEQvF2= MWLTRW5ITVJ?
HSC-3 NVzKeIR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvXOoRKSzVyPUizMlMxPzFizszN MYTTRW5ITVJ?
HTC-C3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TKNGlEPTB;OEOuOFcxOiEQvF2= NEnhc49USU6JRWK=
KY821 M2DtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTh2LkC4PVIh|ryP MVjTRW5ITVJ?
DoTc2-4510 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLFW5dZUUN3ME24OE4zOTh3IN88US=> Ml7pV2FPT0WU
NCI-H1581 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDNOXZ3UUN3ME24OU41PjRzIN88US=> MoPCV2FPT0WU
KARPAS-299 M1P0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD5Z3JpUUN3ME24Ok4yQTd5IN88US=> NFvwbpVUSU6JRWK=
IST-MEL1 NUXudYdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nYZWlEPTB;OE[uPFg4OiEQvF2= M2\M[XNCVkeHUh?=
KP-N-YS NWr5VFVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjpb2dsUUN3ME24PU46ODJ6IN88US=> NIDPPIdUSU6JRWK=
KYSE-410 M13GRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTlzLkSwOFIh|ryP NWnlUnF[W0GQR1XS
TE-10 M{PDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTifopzUUN3ME25NU42PjFzIN88US=> NGj2OpNUSU6JRWK=
SK-MEL-1 NWn2dJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojRTWM2OD17Mj65NVA3KM7:TR?= MV;TRW5ITVJ?
COLO-792 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLmTWM2OD17NT6yOVY1KM7:TR?= Mm[wV2FPT0WU
SCH NWLGUYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HiOmlEPTB;OU[uN|g4PyEQvF2= NVvyfFRsW0GQR1XS
NCI-H1792 M{[1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLyWnlKSzVyPUm2Mlg6QTJizszN NEHlb49USU6JRWK=
NCI-H2029 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfuTWM2OD17Nj65OVY3KM7:TR?= M322SHNCVkeHUh?=
SW684 M3jVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\yR|BYUUN3ME25PE43PjV2IN88US=> M4nudXNCVkeHUh?=
NCI-H209 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFyMD6xNlEh|ryP MXrTRW5ITVJ?
HLE MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1U2lEPTB;MUC1MlI5OiEQvF2= M2nVVXNCVkeHUh?=
GOTO M1G4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFyNz63O|ch|ryP Mmj2V2FPT0WU
NCI-H1793 MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFyOT6yPEDPxE1? Ml;zV2FPT0WU
D-392MG M{nsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrCeGJJUUN3ME2xNVcvOzl6IN88US=> MVrTRW5ITVJ?
SW1990 NF3MT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHlfFVDUUN3ME2xNlAvQTVzIN88US=> NH7MXI5USU6JRWK=
ML-2 NYnOfWl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrwSWNWUUN3ME2xNlEvPjd4IN88US=> NWPNRZV4W0GQR1XS
NCI-H2452 NUfBVYtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF{Mj6yNUDPxE1? MlH0V2FPT0WU
SK-MEL-30 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn60TWM2OD1zMkOuNlQ1KM7:TR?= MUTTRW5ITVJ?
SN12C M37lbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF{ND6xO|Yh|ryP MkjMV2FPT0WU
NCI-H1770 M1vBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXsVnlKSzVyPUGyOU42OTRizszN NIHCRnNUSU6JRWK=
SF268 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF{Nj6xOVgh|ryP NGLIU2tUSU6JRWK=
BALL-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzvTWM2OD1zMk[uNlMh|ryP M1znNnNCVkeHUh?=
COLO-679 NUf2cZl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofJTWM2OD1zMk[uO|U{KM7:TR?= NH3xeZpUSU6JRWK=
A2780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5U2lEPTB;MUK4Mlk5QCEQvF2= M2LLUHNCVkeHUh?=
NCI-H1651 MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fFSGlEPTB;MUOxMlI1OyEQvF2= MlH5V2FPT0WU
NCI-H2087 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XZUmlEPTB;MUOxMlQ5OyEQvF2= NYTPcodQW0GQR1XS
U-87-MG NHrzPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfrN5BpUUN3ME2xN|MvPjB2IN88US=> M{fmXHNCVkeHUh?=
LB2518-MEL M4LacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn0TWM2OD1zM{WuPVk{KM7:TR?= Mn72V2FPT0WU
HCT-116 M1y4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXPWmhQUUN3ME2xN|cvOjF5IN88US=> Ml\VV2FPT0WU
Ca9-22 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXlTWM2OD1zM{muPFM{KM7:TR?= MVPTRW5ITVJ?
COR-L88 NWH2N2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnKVFdKSzVyPUG0Nk4yPCEQvF2= M3\HRXNCVkeHUh?=
CP50-MEL-B MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzGeXplUUN3ME2xOFQvPTBzIN88US=> NIOyUJdUSU6JRWK=
OVCAR-8 M2PXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCwWWExUUN3ME2xOFUvPjN4IN88US=> M{DpfHNCVkeHUh?=
SK-MEL-3 M3jiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;qVWlEPTB;MUS3Mlg4QCEQvF2= NHPhUpVUSU6JRWK=
GT3TKB NV;aUlJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF2OT65Nlgh|ryP MWPTRW5ITVJ?
KYSE-450 NXPZ[GZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF3MT61N|kh|ryP M1fHdnNCVkeHUh?=
CAPAN-1 M1zUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXlPIhKSzVyPUG1N{4xPjRizszN MoWyV2FPT0WU
BEN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PaemlEPTB;MUWzMlkzQCEQvF2= MVTTRW5ITVJ?
NCI-H1304 M3rnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3oWnBKSzVyPUG1OE43QTRizszN M1vsfnNCVkeHUh?=
KU812 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF3OD62O|Qh|ryP M4DUOHNCVkeHUh?=
Capan-2 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF4MD61OVMh|ryP Mm\6V2FPT0WU
A673 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n1bGlEPTB;MU[xMlcxPSEQvF2= MmL0V2FPT0WU
SAS NFSyWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPHTWM2OD1zNkKuOlc5KM7:TR?= M3\QdHNCVkeHUh?=
NY NULwU5pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fETWlEPTB;MU[1MlMyPCEQvF2= NVvUWnFOW0GQR1XS
HCE-4 M3W1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTUTWM2OD1zNk[uPFQ2KM7:TR?= NH;lNmdUSU6JRWK=
MDA-MB-231 MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF5Nz61NFMh|ryP MXLTRW5ITVJ?
no-10 M3rOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHP[4VKSzVyPUG3PE4yOzRizszN NFnYO2lUSU6JRWK=
MZ7-mel Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG3VYtGUUN3ME2xO|gvPDZ5IN88US=> MmTwV2FPT0WU
NCI-H82 NX\xRmV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrOTWM2OD1zOECuNVY2KM7:TR?= MnrKV2FPT0WU
CAL-72 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjOTWM2OD1zOEWuNFU1KM7:TR?= NYr5RpRNW0GQR1XS
NCI-SNU-5 NInuVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPhcG1KSzVyPUG4Ok45PCEQvF2= NGe5dFFUSU6JRWK=
OVCAR-4 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PwVWlEPTB;MUi4MlM{OyEQvF2= MmPtV2FPT0WU
SCC-9 NVfUdXYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXFdVdKSzVyPUG5NUDPxE1? NV;j[YJWW0GQR1XS
KYSE-150 NGXNeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;4eG9KSzVyPUG5NU45QDhizszN M4TIPXNCVkeHUh?=
HT-29 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\pN2lEPTB;MkCxMlIyOiEQvF2= M{HzVHNCVkeHUh?=
COLO-678 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTETWM2OD1{MEGuOFUh|ryP M4DIdXNCVkeHUh?=
NCI-H650 NH70RnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCzTWM2OD1{MEKuNVA{KM7:TR?= NWXwT|ZCW0GQR1XS
HuCCT1 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPaTlFKSzVyPUKwOE4zODhizszN NWPvWWF[W0GQR1XS
SW1116 M164S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QdIRmUUN3ME2yNFcvODd5IN88US=> MluwV2FPT0WU
DBTRG-05MG M322dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\3TWM2OD1{MEeuPVA6KM7:TR?= MXjTRW5ITVJ?
SW982 NHLJUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJyNz65OFgh|ryP NFHIeplUSU6JRWK=
RCM-1 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwTWM2OD1{MUSuO|YzKM7:TR?= MXPTRW5ITVJ?
COLO-320-HSR NV;nbnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrqTWM2OD1{MU[uNVI2KM7:TR?= Mk\sV2FPT0WU
KNS-42 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\tSGlEPTB;MkG2MlU4PCEQvF2= MnTFV2FPT0WU
C2BBe1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjVTWM2OD1{M{GuPVA2KM7:TR?= M3nReHNCVkeHUh?=
CCRF-CEM M{SzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvQPJd3UUN3ME2yOFMvPzl3IN88US=> M3S0WXNCVkeHUh?=
SH-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ2Nj6wPUDPxE1? M17zdnNCVkeHUh?=
LS-1034 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnTWM2OD1{NE[uNlY3KM7:TR?= NFfJTndUSU6JRWK=
NCI-H2347 NFvtW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ2Nz63NVMh|ryP M3rBN3NCVkeHUh?=
RPMI-8866 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ2OT6yO{DPxE1? MXjTRW5ITVJ?
GAK M4DNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor1TWM2OD1{NUOuNFAzKM7:TR?= NWrxdoZxW0GQR1XS
NB6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\m[2lEPTB;MkewMlEh|ryP NGLCR2xUSU6JRWK=
COLO-680N NVP0VW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXsTWM2OD1{N{KuOVI4KM7:TR?= M2TZb3NCVkeHUh?=
RERF-LC-MS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ5Nj6wNFch|ryP Mm\oV2FPT0WU
TGBC11TKB NGi1XW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV60dlM3UUN3ME2yO|gvOTd6IN88US=> NY\MXVNCW0GQR1XS
C8166 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXiTWM2OD1{N{iuOVA3KM7:TR?= Mmr6V2FPT0WU
HDLM-2 M2fZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ7ND60NFkh|ryP NXrjeY9FW0GQR1XS
IGR-1 NHLuWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;yWoVXUUN3ME2yPVUvPjV7IN88US=> Mm\sV2FPT0WU
FADU NH\NcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\mUGlEPTB;Mkm3MlUyKM7:TR?= MmnkV2FPT0WU
L-428 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnhTlJ3UUN3ME2yPVcvPjF4IN88US=> MUXTRW5ITVJ?
LU-65 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfvXmlPUUN3ME2zNFQvOzJizszN NHTUVZJUSU6JRWK=
HEL M4SyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi4O|BjUUN3ME2zNFkvQTh|IN88US=> M{X6UnNCVkeHUh?=
NCI-H810 NWnxWVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7LWpJKSzVyPUOxNE42PyEQvF2= MXfTRW5ITVJ?
C3A MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXDU29KSzVyPUOxNU45ODJizszN NFTBc45USU6JRWK=
NCI-H630 NWrpVGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN|Mj6yPVQh|ryP MknTV2FPT0WU
KP-N-YN M4rKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN2MT6xNlMh|ryP MYLTRW5ITVJ?
MOLT-13 NWX4T3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTN2Mj6zNlYh|ryP M{PmS3NCVkeHUh?=
NCI-H1993 NV3ReVZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnJcGJOUUN3ME2zOFIvOzZ3IN88US=> NW[5WmZOW0GQR1XS
BE-13 MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN2ND6xOlch|ryP Mn7pV2FPT0WU
IST-SL1 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXuTWM2OD1|NEeuOFAyKM7:TR?= NWTqcVJoW0GQR1XS
TE-9 M3[wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\qTWM2OD1|NkOuOVg6KM7:TR?= M{LTSXNCVkeHUh?=
LU-135 NGi0NotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK5fYxYUUN3ME2zOlcvODN3IN88US=> MkC2V2FPT0WU
T84 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN5ND63NVIh|ryP M1\G[3NCVkeHUh?=
K-562 M33mWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;pZWlEPTB;M{izMlM3KM7:TR?= NEjnUo9USU6JRWK=
SBC-5 NV7VPHBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ixZWlEPTB;M{i2Mlk5PSEQvF2= NX;2d3pNW0GQR1XS
NB17 NWHmb3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjGeIZKSzVyPUO5Nk42QTZizszN M1fnXnNCVkeHUh?=
NCI-H2052 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN7OD60O|Ih|ryP NILwZoVUSU6JRWK=
HCC38 NG\U[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jZSGlEPTB;NECxMlU6OyEQvF2= MlLqV2FPT0WU
NCI-H69 M{K0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG0ZZlKSzVyPUS0NU4xQDNizszN M3HEVXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]

+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]

+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
15% Captisol
For best results, use promptly after mixing.
17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID